Mount Sinai School of Medicine licenses avian flu vaccine to Avimex
NEW YORK, NY Mount Sinai School of Medicine today announced that it has entered into a territory limited license agreement with Avimex* Animal Health. The privately owned world-leader in the avian influenza H5 emulsified vaccine market will use Mount Sinai's patented live recombinant Newcastle disease technology that contains an insertion of the H5 gene, for use in Brazil, India, Japan, Mexico,...